Advertisement
Research Article Free access | 10.1172/JCI102171
Division of Internal Medicine, University of Minnesota Medical School, Minneapolis
1Presented at the Second National Symposium on Recent Advances in Antibiotics Research held in Washington, D. C., April 11-12, 1949, under the auspices of the Antibiotics Study Section, National Institutes of Health, Public Health Service, Federal Security Agency.
2This investigation was supported (in part) by a research grant from the Division of Research Grants and Fellowships of the National Institutes of Health, United States Public Health Service, and by a grant from the Lederle Laboratories. The aureomycin was supplied by the Lederle Laboratories; the dihydrostreptomycin, by E. R. Squibb Company; polymyxin, by the Stamford Research Laboratories, American Cyanamid Company; bacitracin and Q-19, by the Upjohn Company; and chloromycetin, by Parke, Davis and Company.
Find articles by Yow, E. in: JCI | PubMed | Google Scholar
Division of Internal Medicine, University of Minnesota Medical School, Minneapolis
1Presented at the Second National Symposium on Recent Advances in Antibiotics Research held in Washington, D. C., April 11-12, 1949, under the auspices of the Antibiotics Study Section, National Institutes of Health, Public Health Service, Federal Security Agency.
2This investigation was supported (in part) by a research grant from the Division of Research Grants and Fellowships of the National Institutes of Health, United States Public Health Service, and by a grant from the Lederle Laboratories. The aureomycin was supplied by the Lederle Laboratories; the dihydrostreptomycin, by E. R. Squibb Company; polymyxin, by the Stamford Research Laboratories, American Cyanamid Company; bacitracin and Q-19, by the Upjohn Company; and chloromycetin, by Parke, Davis and Company.
Find articles by Spink, W. in: JCI | PubMed | Google Scholar
Published September 1, 1949 - More info